A combination of coenzyme Q10, feverfew and magnesium for migraine prophylaxis: a prospective observational study

Table 2 Number of days with migraine headache per month and 50% reduction in this number

	ITT population (n = 68)	PP population (n = 62)
No. of days with migraine headache per month (mean ± SD)
Baseline phase	4.9 ± 2.6	5.1 ± 2.5
1^st month	2.4 ± 3.1*	2.5 ± 3.2*
2^nd month	1.9 ± 2.3*	2 ± 2.4*
3^rd month	1.3 ± 1.5*	1.4 ± 1.6*
% of patients with ≥ 50% reduction in no. of days with migraine headache per month (% [CI 95%])
1^st month	63.2% [51.8–74.7]	64.5% [52.6–76.4]
2^nd month	70.6% [59.8–81.4]	71.0% [59.7–82.3]
3^rd month	75% [64.7–85.3]	74.2% [63.3–85.1]

ISSN: 2662-7671